Biomea Competitors
| BMEA Stock | USD 1.33 0.08 6.40% |
Biomea Fusion vs Sutro Biopharma Correlation
Average diversification
The correlation between Biomea Fusion and STRO is 0.18 (i.e., Average diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Biomea Fusion and STRO in the same portfolio, assuming nothing else is changed.
Moving against Biomea Stock
| 0.48 | OB3 | OPTIBIOTIX HLTH PLC | PairCorr |
| 0.47 | ABNX | Abionyx Pharma SA | PairCorr |
| 0.41 | PYC | Physiomics Plc | PairCorr |
| 0.38 | CMB | Cambium Bio Earnings Call This Week | PairCorr |
| 0.38 | SABSW | SAB Biotherapeutics | PairCorr |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Biomea Fusion's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Biomea Fusion Competition Correlation Matrix
Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Biomea Fusion and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Biomea and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Biomea Fusion does not affect the price movement of the other competitor.
High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Biomea Stock performing well and Biomea Fusion Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Biomea Fusion's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| RPTX | 2.16 | 0.56 | 0.24 | 2.17 | 1.47 | 3.95 | 35.71 | |||
| CBUS | 5.68 | 1.64 | 0.26 | 2.38 | 5.51 | 12.07 | 33.18 | |||
| IMUX | 4.17 | 0.34 | 0.08 | 0.27 | 3.97 | 11.29 | 22.02 | |||
| GUTS | 5.28 | (0.75) | 0.00 | (0.92) | 0.00 | 11.89 | 85.71 | |||
| UNCY | 3.92 | 0.46 | 0.10 | 0.57 | 4.25 | 8.04 | 20.63 | |||
| CAMP | 5.69 | 0.21 | 0.03 | 0.15 | 7.83 | 12.76 | 47.02 | |||
| ALXO | 5.47 | 1.06 | 0.18 | (1.63) | 5.23 | 13.04 | 23.85 | |||
| PMVP | 2.57 | (0.33) | 0.00 | (0.45) | 0.00 | 6.36 | 17.05 | |||
| ADVM | 3.39 | 0.40 | 0.10 | 0.37 | 3.70 | 10.34 | 40.97 | |||
| STRO | 4.81 | 1.21 | 0.22 | 0.85 | 4.68 | 11.87 | 29.10 |
Cross Equities Net Income Analysis
Compare Biomea Fusion and related stocks such as Repare Therapeutics, Cibus Global LLC, and Immunic Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| RPTX | (7.8 M) | (7.8 M) | (7.8 M) | (7.8 M) | (7.8 M) | (7.8 M) | (7.8 M) | (7.8 M) | (14.3 M) | (27.2 M) | (53.4 M) | (106.9 M) | (29 M) | (93.8 M) | (84.7 M) | (76.2 M) | (80 M) |
| CBUS | (5.9 M) | (5.9 M) | (5.9 M) | (5.9 M) | (5.9 M) | (5.9 M) | (12.1 M) | (26 M) | (27.9 M) | (39.6 M) | (44.8 M) | (29.2 M) | (16.9 M) | (267.6 M) | (251.4 M) | (226.2 M) | (214.9 M) |
| IMUX | (5.9 M) | (5.9 M) | (6.7 M) | (32.7 M) | (47.7 M) | (52 M) | (41 M) | (52.1 M) | (41.5 M) | (34.8 M) | (44 M) | (92.8 M) | (120.4 M) | (93.6 M) | (100.5 M) | (90.5 M) | (85.9 M) |
| GUTS | (30.6 M) | (30.6 M) | (30.6 M) | (30.6 M) | (30.6 M) | (30.6 M) | (30.6 M) | (30.6 M) | (30.6 M) | (30.5 M) | (38.7 M) | (46.5 M) | (77.1 M) | (68.7 M) | (68.7 M) | (61.8 M) | (64.9 M) |
| UNCY | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (2.3 M) | (2.5 M) | (10.6 M) | (18.1 M) | (30.5 M) | (36.7 M) | (33.1 M) | (31.4 M) |
| CAMP | (5.7 M) | 5.2 M | 44.6 M | 11.8 M | 16.5 M | 16.9 M | (7.2 M) | 16.6 M | 18.4 M | (78.8 M) | (21.2 M) | (31.1 M) | (44.2 M) | (49.3 M) | (51.8 M) | (46.6 M) | (44.3 M) |
| ALXO | (13.7 M) | (13.7 M) | (13.7 M) | (13.7 M) | (13.7 M) | (13.7 M) | (13.7 M) | (13.7 M) | (13.7 M) | (19.2 M) | (45.7 M) | (83.5 M) | (123.5 M) | (160.8 M) | (134.8 M) | (121.4 M) | (127.4 M) |
| PMVP | (17.5 M) | (17.5 M) | (17.5 M) | (17.5 M) | (17.5 M) | (17.5 M) | (17.5 M) | (17.5 M) | (17.5 M) | (25.4 M) | (34.4 M) | (57.8 M) | (73.3 M) | (69 M) | (58.7 M) | (52.8 M) | (55.5 M) |
| STRO | 1.7 M | 1.7 M | 1.7 M | 1.7 M | 1.7 M | 1.7 M | 1.7 M | (19.7 M) | (35.3 M) | (55.7 M) | (32.1 M) | (105.5 M) | (119.2 M) | (106.8 M) | (227.5 M) | (204.7 M) | (194.5 M) |
Biomea Fusion and related stocks such as Repare Therapeutics, Cibus Global LLC, and Immunic Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Biomea Fusion financial statement analysis. It represents the amount of money remaining after all of Biomea Fusion operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Biomea Fusion Competitive Analysis
The better you understand Biomea Fusion competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Biomea Fusion's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Biomea Fusion's competition over several years is one of the best ways to analyze its investment potential.| Better Than Average | Worse Than Peers | View Performance Chart |
Biomea Fusion Competition Performance Charts
Five steps to successful analysis of Biomea Fusion Competition
Biomea Fusion's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Biomea Fusion in relation to its competition. Biomea Fusion's competition analysis typically involves several steps, including:- Identifying the key players in the market: This involves identifying the major competitors of Biomea Fusion in the market, both direct and indirect, as well as new entrants and disruptive technologies.
- Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
- Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Biomea Fusion's competitive landscape.
- Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Biomea Fusion, and developing a strategy to address them.
- Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Complement your Biomea Fusion position
In addition to having Biomea Fusion in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Broad Sovereign ETFs Thematic Idea Now
Broad Sovereign ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Broad Sovereign ETFs theme has 14 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Broad Sovereign ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Biomea Fusion Correlation with its peers. For information on how to trade Biomea Stock refer to our How to Trade Biomea Stock guide.You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biomea Fusion. Projected growth potential of Biomea fundamentally drives upward valuation adjustments. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Biomea Fusion assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Investors evaluate Biomea Fusion using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Biomea Fusion's intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. External factors like market trends, sector rotation, and investor psychology can cause Biomea Fusion's market price to deviate significantly from intrinsic value.
It's important to distinguish between Biomea Fusion's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Biomea Fusion should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, Biomea Fusion's market price signifies the transaction level at which participants voluntarily complete trades.